Ribociclib (CAS 1211441-98-3)
Alternate Names:
LEE011 LEE-011 LEE 011 Ribociclib
CAS Number:
1211441-98-3
Molecular Weight:
434.54
Molecular Formula:
C23H30N8O
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Ribociclib (CAS 1211441-98-3) References
- Ribociclib for post-menopausal women with HR+/HER2- advanced or metastatic breast cancer. | Zangardi, ML., et al. 2017. Expert Rev Clin Pharmacol. 10: 1169-1176. PMID: 28875723
- Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. | Tripathy, D., et al. 2018. Lancet Oncol. 19: 904-915. PMID: 29804902
- Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. | Büyükkaramikli, NC., et al. 2019. Pharmacoeconomics. 37: 141-153. PMID: 30194622
- Ribociclib mitigates cisplatin-associated kidney injury through retinoblastoma-1 dependent mechanisms. | Kim, JY., et al. 2020. Biochem Pharmacol. 177: 113939. PMID: 32229099
- Clinical Pharmacokinetics and Pharmacodynamics of the Cyclin-Dependent Kinase 4 and 6 Inhibitors Palbociclib, Ribociclib, and Abemaciclib. | Groenland, SL., et al. 2020. Clin Pharmacokinet. 59: 1501-1520. PMID: 33029704
- Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences. | Braal, CL., et al. 2021. Drugs. 81: 317-331. PMID: 33369721
- Ribociclib Cytotoxicity Alone or Combined With Progesterone and/or Mitotane in in Vitro Adrenocortical Carcinoma Cells. | Abate, A., et al. 2022. Endocrinology. 163: PMID: 34875044
- Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer. | Kahraman, S., et al. 2023. Future Oncol. 19: 727-736. PMID: 37133230
- Abemaciclib, Palbociclib, and Ribociclib in Real-World Data: A Direct Comparison of First-Line Treatment for Endocrine-Receptor-Positive Metastatic Breast Cancer. | Cejuela, M., et al. 2023. Int J Mol Sci. 24: PMID: 37239834
- Differences in metabolic transport and resistance mechanisms of Abemaciclib, Palbociclib, and Ribociclib. | Zhu, Z. and Zhu, Q. 2023. Front Pharmacol. 14: 1212986. PMID: 37475713
Inhibitor of:
1700018G05Rik, 3110052M02Rik, 4932411N23Rik, 4933404M19Rik, 4933411G11Rik, 4E-BP2, 9330159F19Rik, ALS2CR7, ANKRD20A1, ANKRD20A3, BEND6, Beta-NAP, C12orf63, C20orf43, C430048L16Rik, C6orf1, CCDC167, CCNI2, CCNJL, CCRK, Cdc123, CDD, Cdk4, CDK5RAP, Cdk6, CdkL4, Cdx2, Cdx4, CIRP, CKAP2L, Cks2, CNTD1, cyclin δ-1, cyclin δ-2, cyclin δ-3, cyclin A-type, cyclin D1, cyclin D2, cyclin D3, cyclin E, cyclin E2, cyclin F, cyclin I, cyclin M4, cyclin Y, cyclin YL3, D-type cyclin, D1Ertd622e, DABP, DAN, Dcpp2, DMXL1, DNB5, DOC1, E2F-1, E2F-7, E2F-8, EG435366, EHZF, FAM111B, FAM117A, FAM127B, FAM149B1, FAM160A1, FBXW22, FLJ32549, GEMC1, Gm606, Gm75, GMD, GPN3, Gtlf3b, HEXIM2, HIP14L, HST, INCA1, Ki-67, KKIALRE, KPRP, LAGE-3, LIN-52, LIN37, LOC341346, LOC441150, LRP16, MAGE-D4B, MCEMP1, Mcpr1, MIPU1, MPc3_CBX8, MycN, NCYM, Olfr1354, Olfr209, Olr1029, Olr1060, Olr1204, Olr1206, Olr1218, Olr1235, Olr1245, Olr1259, Olr1292, Olr1558, Olr157, Olr184, Olr367, Olr390, Olr484, Olr541, Olr653, Olr704, Olr726, Olr744, Olr766, Olr773, Olr951, OTTMUSG00000016588, p130, p15, p18, p27, p35, p39 (CDK5R), p57, PCNP, PCTAIRE-2, Peregrin, Pet117, Pinch-2, PITSLRE B, PL6, POGZ, RBBP9, Repetin, RIA1, SERTAD4, Sic1, Sp3, SPC12, Speedy E3, Speedy E6, SS18L2, TCHHL1, TOB1, V1RG1, WDR66, ZFP260, ZMAT4, ZNF2, ZNF20, ZNF264, ZNF486, ZNF492, ZNF703, ZNF705A, and ZSCAN16.Activator of:
CCRK, Cdk10, Cig2, Cks1, cyclin δ-1, cyclin YL3, DP-1, LIN-54, PPIL4, SDCCAG10, Speedy A, and WDR61.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Ribociclib, 10 mg | sc-507367 | 10 mg | $450.00 |